

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **March 9, 2018**

**Contravir Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation or organization)

**000-55020**  
(Commission  
File Number)

**46-2783806**  
(IRS Employer  
Identification No.)

**399 Thornall Street, First Floor**  
**Edison, NJ 08837**  
(Address of principal executive offices)

Registrant's telephone number, including area code: **(732) 902-4000**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On March 9, 2018 ContraVir Pharmaceuticals, Inc. (the “Company”) held its previously adjourned 2017 Annual Meeting of Stockholders (the “Meeting”). At the Meeting, the Company’s stockholders approved Proposal 4 which is an amendment to its Certificate of Incorporation to effect a reverse stock split of its issued and outstanding common stock at a specific ratio, within a range of 1-for-5 and 1-for-20, to be determined by its Board of Directors in its sole discretion and effected, if at all, on or before February 21, 2019.

Set forth below are the final voting results for Proposal 4:

*Proposal No. 4 — Amendment to Certificate of Incorporation to Effect a Reverse Stock Split.*

<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstained</b>
43,620,042	3,570,682	461,533

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 9, 2018

CONTRAVIR PHARMACEUTICALS, INC.

By: /s/ James Sapirstein  
James Sapirstein  
Chief Executive Officer